

Regd. & Corp. Office:
1506, Chiranjiv Tower,
43, Nehru Place,
New Delhi - 110019 (INDIA)

Tel.: 011 - 47589500-51 (50 Lines),
E-mail: info@medicamen.com
Web: www.medicamen.com
CIN No.: L74899DL1993PLC056594

Ref: STEX/Announcement/2024-25

Date: 25.10.2024

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001

National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla complex
Bandra(E) Mumbai- 400051

Code No: 531146

Symbol: MEDICAMEQ

Sub: US FDA Approved the sterile injectable Oncology Formulation facility at Haridwar and Establishment Inspection Report (EIR) released

Dear Sir/ Ma'am,

Pursuant to regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that:

The United States Food and Drug Administration (US FDA) issued FMD-145 copy of EIR for the sterile injectable line - Bortezomib for Injection 3.5 mg / vial (Lyophilised) for Oncology Formulation facility of Medicamen Biotech Limited located at Plot No. 84 & 85, Sector-6A, IIE, Sidcul, BHEL, Ranipur, Haridwar- 249403 based on the inspection concluded on April 26, 2024 and has now released Establishment Inspection Report (EIR).

This is for your information and records.

Thanking You

Yours truly,
For Medicamen Biotech Limited

Parul Choudhary
Company Secretary
ACS: 44157